European Patent Application EP3887403A1, filed by ABL Bio Inc., has been published. The patent covers an anti-4-1BB antibody and its therapeutic applications, particularly in the field of oncology. This publication signifies the formal disclosure of the invention and initiates a period where third parties may oppose the grant of the patent.

This is a patent publication, not a regulatory rule or enforcement action. It does not impose new compliance obligations on regulated entities. Companies in the pharmaceutical and biotechnology sectors should note this publication for competitive intelligence and intellectual property landscape monitoring. No immediate action is required from compliance officers.